The scalability gap in R&D is a growing concern in many fields that require scalable assay development.
Many biotech assays fail during scale-up because separation performance changes with volume. Scalable assay development is essential to ensure what worked reliably at 100 µL becomes efficient at several milliliters.
This is not a failure of the assay—it is a failure of scalability design. By contrast, developing scalable assays improves reproducibility and efficiency.
Why magnetic separation does not automatically scale
As volumes increase:
- Bead sedimentation dynamics change
- Separation times increase unpredictably
- Yield and purity become inconsistent
These issues arise when separation force is not controlled across scales. To avoid these challenges, scalable assay development must focus on force consistency.
Bench-scale industrial behavior
R&D teams benefit from simulating industrial separation behavior early. This means working with systems that apply constant magnetic force regardless of volume.
Such systems allow:
- Direct transfer of protocols from bench to pilot
- Fewer re-optimization steps
- More reliable scale-up projections
Designing with the end in mind
Scalability should be treated as a core requirement in assay development—not a future concern. This underlines the importance of scalable development when designing an assay.
Key takeaway
Assays designed under scalable separation conditions are far more likely to survive the transition from R&D to pilot manufacturing. Moreover, scalable assay development increases robustness and reproducibility.
Discover R&D Magnetic Bead Separators
